Crossmark

How COVID-19 will change the management of other respiratory viral infections

Published Online: 2021-08-11

Published Print: 2021-10

Authors

Arabi, Yaseen M. https://orcid.org/0000-0001-5735-6241
Derde, Lennie P. G. https://orcid.org/0000-0002-3577-5629
Timsit, Jean-François https://orcid.org/0000-0002-6063-7383
License Information

Text and Data Mining valid from 2021-08-11

Version of Record valid from 2021-08-11
More Information

Article History

Received: 23 May 2021

Accepted: 19 July 2021

First Online: 11 August 2021

Declarations

:

: YMA: Investigator on REMAP-CAP trial, Investigator on COVI-PRONE trial, Principal investigator on Helmet-COVID trial, member of Member of the COVID-19 guideline committee SCCM/ESICM/SSC.LPGD: EU FP7-HEALTH-2013-INNOVATION-1, PREPARE grant number 602525, H2020 RECOVER grant agreement No 101003589, Dutch ZonMw grant (ANACOR-IC) Projectnr 10150062010003, Chair of the EU RMC, ITSC member and involved in several DSWGs REMAP-CAP, Member of the COVID-19 guideline committee SCCM/ESICM/SSC, Member of the ESICM COVID-19 taskforce, Chair of the Dutch intensivists (NVIC) taskforce infectious threats.JFT is the PI of the COVIDICUS academic research program comparing 2 doses of corticosteroids and oxygenation modes (NCT04344730).JFT participated to 2 advisory boards and antiviral therapies directed against sars-Cov2 (Merck and Gilead).

Free to read: This content has been made available to all.

Document is current